HDCTHigh-Dose Chemotherapy (cancer treatment)
HDCTHalf Day City Tour (various locations)
HDCTHeritable Disorder of Connective Tissue
HDCTHigh-Dose Cytotoxic Therapy
HDCTHigh Definition Computed Tomography
HDCTHybrid Discrete Cosine Transform
References in periodicals archive ?
To save the space, we only consider the most recent thirteen models: FT [5], HC [6], RC [6], LR [8], PD [9], GC [12], HI [10], GMR [11], BMS [13], UFO [14], AMC [15], HDCT [16], and SO [17].
Caption: Figure 2: Saliency maps (from left to right, top to down): input, G-Truth, IT [1], LC [2], SR [3], GB [4], FT [5], HC [6], RC [6], LR [8], PD [9], HI [10], GMR [11], GC [12], BMS [13], UFO [14], AMC [15], HDCT [16], SO [17], and ours.
8] Nonstandard abbreviations: HER, human epidermal growth factor receptor; EGFR, epidermal growth factor receptor; ECD, extracellular domain; MMP, matrix metalloproteinase; Mab, monoclonal antibody; MBC, metastatic breast cancer; OS, overall survival; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; FDA, Food and Drug Administration; PBC, primary breast cancer; CISH, chromogenic in situ hybridization; TTP, time to progression; DFS, disease-free survival; HDCT, high-dose chemotherapy; ER, estrogen receptor; CMF, cyclophosphamide-methotrexate-5-fluorouracil; and CEA, carcinoembryonic antigen.
A prognostic classification for germ cell tumour patients undergoing first salvage treatment based on a large international database of patients treated with contemporary CDCT or HDCT has been developed by the International Prognostic Factor Study Group (IPFSG).
Since 1990, a consistent approach offering single course HDCT as consolidation after response to a full course of CDCT has been used at our institution.
The study population included 179 consecutive patients [42 men and 137 women; mean (SD) age, 47 [+ or -] 11 years] treated with HDCT for aggressive malignancy between November 1999 and December 2000 in our Institute.
A subsequent retrospective analysis from the same group showed an improvement in PFS and OS in each prognostic group (with the exception of OS in the low-risk group) for upfront HDCT versus CDCT.
Ideally, properly constructed prospective randomized trials must be set up to address the issue at hand, in view of the global differences in what constitutes HDCT and CDCT regimens, and the worldwide variability in treating this disease where HDCT may be offered as first, second or even third-line therapy.
Patients who failed to be cured with a standard dose option and are well enough to tolerate it, HDCT with transplantation should be offered before declaring the relapsed disease incurable.
We believe HDCT technologies are transformational and we're excited about the clinical possibilities that they may enable.
IMN: How can clinicians distinguish JHS from other HDCTs, such as Ehlers-Danlos syndrome?
Symptoms of HDCTs are extremely variable, and some disorders can pose severe health risks even when affected individuals have no symptoms.